Market reference price and drug price change trend of Erlotinib in 2026

Erlotinib is a targeted drug commonly used to treat EGFR mutation-positive non-small cell lung cancer. Since it was launched in China and included in medical insurance, the accessibility of erlotinib has significantly improved, and patients can purchase the drug at a lower price in hospital pharmacies. The current price in the domestic market is around a few hundred yuan. The specific reimbursement ratio and cost will vary depending on regional medical insurance policies. Patients need to confirm with local medical institutions.

In the international market, erlotinib is also available as original drug and generic drug. The price of original drugs is relatively high, while the price of generic drugs produced in countries such as Laos is relatively cheap, about 400 yuan per box. This type of generic drugs is basically the same as the original drug in terms of drug ingredients and efficacy, providing a more feasible medication option for patients with limited economic conditions.

The price trend of erlotinib is affected by a variety of factors, including adjustments to medical insurance policies, market supply, pricing strategies of pharmaceutical companies, and fluctuations in international exchange rates. The coverage of domestic medical insurance has reduced the burden of long-term medication on patients, and at the same time prompted some hospital pharmacies to maintain price stability in procurement and sales, thereby ensuring continued treatment for patients.

Overall, the price of erlotinib in the domestic market is relatively stable and affordable, which provides convenience for patients to continue targeted therapy. When choosing drugs, patients can reasonably arrange procurement channels and medication plans based on medical insurance policies, drug sources and economic conditions to ensure treatment effects and economic affordability.

Keyword tags:

Erlotinib, market reference price, 2026 annual trends, medical insurance policies, price changes, imported drugs, generic drugs, economic burden

Reference materials:https://www.cancer.gov/about-cancer/treatment/drugs/erlotinib